For research use only. Not for therapeutic Use.
TRC-766 is a negative control of RTC-5 (TRC-382). TRC-766 binds protein phosphatase 2A (PP2A) and does not activate the phosphatase[1].
As a pharmacologic control, the cells are treated with increasing doses of TRC-766, which is structurally similar to PP2A (SMAP) but biologically inactive. TRC-766 lacks a key N-H sulfonamide hydrogen bond donor. While TRC-766 still binds PP2A, it does not activate the phosphatase and therefore it was postulated to not affect cell viability[1].
| Catalog Number | I045459 |
| CAS Number | 1810734-44-1 |
| Synonyms | N-[3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl]-N-methyl-4-(trifluoromethoxy)benzenesulfonamide |
| Molecular Formula | C25H24ClF3N2O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C25H24ClF3N2O3S/c1-30(35(32,33)22-13-11-21(12-14-22)34-25(27,28)29)15-4-16-31-23-6-3-2-5-18(23)7-8-19-9-10-20(26)17-24(19)31/h2-3,5-6,9-14,17H,4,7-8,15-16H2,1H3 |
| InChIKey | HXSYJRNSDWIKPO-UHFFFAOYSA-N |
| SMILES | CN(CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl)S(=O)(=O)C4=CC=C(C=C4)OC(F)(F)F |
| Reference | [1]. Kimberly McClinch, et al. Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. Cancer Res. 2018 Apr 15;78(8):2065-2080. |
